The Road to Success: Selectively Targeting TGF-β for Antifibrotic Drug Development & Harnessing the Translational Insights for Immuno-Oncology
Time: 9:00 am
day: Day One
Details:
- Highlighting the discovery and development of PLN-74809, a dual selective integrin inhibitor for pulmonary fibrosis
- Uncovering Pliant’s translational approach and successful Phase 2 results in IPF
- Reprogramming the tumor microenvironment with selective inhibition of TGF-β
- Discussing blocking integrin activation of TGF-β to increase checkpoint inhibitor efficacy and targeting immune and stromal activation of TGF-β